<DOC>
	<DOC>NCT00214734</DOC>
	<brief_summary>The primary objective of this post-authorization safety surveillance is to measure the incidence of adverse events that are at least possibly related to ADVATE use, in subjects receiving ADVATE in routine clinical practice.</brief_summary>
	<brief_title>ADVATE Post Authorization Safety Surveillance</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<criteria>Subject has moderate or severe hemophilia A (baseline FVIII less than or equal to 5%) Subject currently has no measurable FVIII inhibitor titer greater than or equal to 1 BU (Bethesda or Nijmegen method) Subject has been prescribed ADVATE by their treating physician Subject may be of any age Subject or parent/legally authorized representative has provided written informed consent</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>